NTO-1151 is under clinical development by Ology Bioservices and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase II drugs for Neuroendocrine Tumors have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NTO-1151’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NTO-1151 overview
NTO-1151 is under development for the treatment of neuroendocrine tumors. It is under development for the treatment of previously untreated solid tumors such as cervical, vaginal cancers. Triapine is administered as intravenously and orally. It is a synthetic heterocyclic carboxaldehyde thiosemicarbazone. It targets the enzyme ribonucleotide reductase. It was also under development for the treatment of aggressive myeloproliferative disorders (MPDs) including chronic myelomonocytic leukemia (CMML), chronic myelogenous leukemia, advanced prostate cancer, recurrent/unresectable/metastatic pancreatic carcinoma, unresectable or metastatic biliary duct or gallbladder cancer, recurrent renal cell carcinoma, advanced or metastatic adrenocarcinoma of the pancreas, metastatic non-small cell lung cancer, refractory metastatic breast cancer, recurrent or metastatic adenocarcinoma of the esophagus or gastroesophageal junction, recurrent or persistent platinum-resistant ovarian epithelial or primary peritoneal cancer, metastatic bile duct cancer, stage III or stage IV recurrent non-small cell lung cancer and as a second line treatment of non-small cell lung cancer and also for advanced solid tumors.
Ology Bioservices overview
Ology Bioservices is an US based integrated biopharmaceutical company. The company provides contract development and manufacturing services. The company manufactures biopharmaceutical products which include vaccines, antibodies, protein therapies and medical devices.
For a complete picture of NTO-1151’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
